- call +1-201-465-4211
- email sales@mrinsights.biz
Psoriasis is considered to be a persistent skin disorder that is characterized mainly by skin irritation and scaly rashes where the skin cells multiply up to 10 times faster than normal. Psoriasis majorly affects the knees, elbows, and scalp. The major objective of the therapy for this disease is to stop the skin cells from growing so quickly. The therapeutic approach for psoriasis depends upon the severity and amount of skin affected by the same.
Scope of the Report:
This report studies the Psoriasis Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Psoriasis Therapeutics market by product type and applications/end industries.
The global Psoriasis Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Psoriasis Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Astellas Pharma Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
F. Hofffmann-La Roche
GlaxoSmithKline plc
Merck & Co., Inc.
Valeant Pharmaceuticals International, Inc.
Biocon Limited
Eli Lilly and Company
G & W Laboratories Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
TNF Inhibitors
PDE4 Inhibitors
Interleukin Blockers
Others
Market Segment by Applications, can be divided into
Oral
Parenteral
Topical
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Psoriasis Therapeutics Market Overview
1.1 Product Overview and Scope of Psoriasis Therapeutics
1.2 Classification of Psoriasis Therapeutics by Types
1.2.1 Global Psoriasis Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Psoriasis Therapeutics Revenue Market Share by Types in 2017
1.2.3 TNF Inhibitors
1.2.4 PDE4 Inhibitors
1.2.5 Interleukin Blockers
1.2.6 Others
1.3 Global Psoriasis Therapeutics Market by Application
1.3.1 Global Psoriasis Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Topical
1.4 Global Psoriasis Therapeutics Market by Regions
1.4.1 Global Psoriasis Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Psoriasis Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Psoriasis Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Psoriasis Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Astellas Pharma Inc.
2.1.1 Business Overview
2.1.2 Psoriasis Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Pharma Inc. Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca plc
2.2.1 Business Overview
2.2.2 Psoriasis Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca plc Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Boehringer Ingelheim GmbH
2.3.1 Business Overview
2.3.2 Psoriasis Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Boehringer Ingelheim GmbH Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 F. Hofffmann-La Roche
2.4.1 Business Overview
2.4.2 Psoriasis Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hofffmann-La Roche Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 GlaxoSmithKline plc
2.5.1 Business Overview
2.5.2 Psoriasis Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GlaxoSmithKline plc Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Merck & Co., Inc.
2.6.1 Business Overview
2.6.2 Psoriasis Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Merck & Co., Inc. Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Valeant Pharmaceuticals International, Inc.
2.7.1 Business Overview
2.7.2 Psoriasis Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Valeant Pharmaceuticals International, Inc. Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Biocon Limited
2.8.1 Business Overview
2.8.2 Psoriasis Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Biocon Limited Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Eli Lilly and Company
2.9.1 Business Overview
2.9.2 Psoriasis Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Eli Lilly and Company Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 G & W Laboratories Inc.
2.10.1 Business Overview
2.10.2 Psoriasis Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 G & W Laboratories Inc. Psoriasis Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Psoriasis Therapeutics Market Competition, by Players
3.1 Global Psoriasis Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Psoriasis Therapeutics Players Market Share
3.2.2 Top 10 Psoriasis Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Psoriasis Therapeutics Market Size by Regions
4.1 Global Psoriasis Therapeutics Revenue and Market Share by Regions
4.2 North America Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Psoriasis Therapeutics Revenue by Countries
5.1 North America Psoriasis Therapeutics Revenue by Countries (2013-2018)
5.2 USA Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Psoriasis Therapeutics Revenue by Countries
6.1 Europe Psoriasis Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Psoriasis Therapeutics Revenue by Countries
7.1 Asia-Pacific Psoriasis Therapeutics Revenue by Countries (2013-2018)
7.2 China Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Psoriasis Therapeutics Revenue by Countries
8.1 South America Psoriasis Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Psoriasis Therapeutics by Countries
9.1 Middle East and Africa Psoriasis Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Psoriasis Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Psoriasis Therapeutics Market Segment by Type
10.1 Global Psoriasis Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Psoriasis Therapeutics Market Forecast by Type (2018-2023)
10.3 TNF Inhibitors Revenue Growth Rate (2013-2023)
10.4 PDE4 Inhibitors Revenue Growth Rate (2013-2023)
10.5 Interleukin Blockers Revenue Growth Rate (2013-2023)
10.6 Others Revenue Growth Rate (2013-2023)
11 Global Psoriasis Therapeutics Market Segment by Application
11.1 Global Psoriasis Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Psoriasis Therapeutics Market Forecast by Application (2018-2023)
11.3 Oral Revenue Growth (2013-2018)
11.4 Parenteral Revenue Growth (2013-2018)
11.5 Topical Revenue Growth (2013-2018)
12 Global Psoriasis Therapeutics Market Size Forecast (2018-2023)
12.1 Global Psoriasis Therapeutics Market Size Forecast (2018-2023)
12.2 Global Psoriasis Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Psoriasis Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Psoriasis Therapeutics Picture
Table Product Specifications of Psoriasis Therapeutics
Table Global Psoriasis Therapeutics and Revenue (Million USD) Market Split by P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
